Tissue-agnostic cancer therapies: promise, reality, and the path forward by Vivek Subbiah

Get full text

Advancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancer by Edwin Lin, Ying-Chun Lo, Vivek Subbiah, Rajat Thawani, Aakash Desai

Get full text

Pembrolizumab in Patients with Advanced Miscellaneous Rare Cancers: Results from a Phase 2 Basket Trial by Mirella Nardo, Camila Braganca Xavier, Bettzy Stephen, Jeffrey A. How, Justin Moyers, Vivek Subbiah, David S. Hong, Aung Naing

Get full text

A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours by Yasutoshi Kuboki, Hendrik-Tobias Arkenau, Vivek Subbiah, Timothy Price, Gerald Falchook, Hans Prenen, Rafal Dziadziuszko, Hansen Wong, Iwona Lugowska, Daniel Tan, Weibing Shi, Ryota Shibaki, Min Hee Hong, Sant P Chawla, Jose G Monzon, Mun Hui, Caio Max Rocha Lima, Kejia Wang, Antreas Hindoyan, Mira Kistler

Get full text

Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial by Mirella Nardo, Mohamed A. Gouda, Matthew J. Reilley, Amadeo B. Biter, Joann Lim, Stacie A. Bean, Ly M. Nguyen, Priya R. Bhosale, Casey R. Ager, Coline A. Couillault, Sarina A. Piha-Paul, Siqing Fu, Apostolia M. Tsimberidou, Timothy A. Yap, Aung Naing, Jordi Rodon, Vivek Subbiah, Daniel D. Karp, Michael A. Curran, David S. Hong

Get full text

Precision Oncology: A Global Perspective on Implementation and Policy Development by Denis Horgan, Marcel Tanner, Charu Aggarwal, David Thomas, Surbhi Grover, Lina Basel-Salmon, Rodrigo Dienstmann, Tira Jing Ying Tan, Woong-Yang Park, Hadi Mohamad Abu Rasheed, Lillian L. Siu, Brigette Ma, Rocío Ortiz-López, Marc Van den Bulcke, Silvia Castillo Taucher, Andrea Ferris, Naureen Starling, Umberto Malapelle, John Longshore, Hugo Alberto Barrera Saldaña, Vivek Subbiah

Get full text

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma by Omar Alhalabi, Mohamed A. Gouda, Denái R. Milton, Hassan Ahmed Momin, Bulent Yilmaz, Bettzy Stephen, Chinenye Lynette Ejezie, Justin Tyler Moyers, Serdar A. Gurses, Jeffrey How, Siqing Fu, Jordi Rodon, David S. Hong, Sarina A. Piha‐Paul, Vivek Subbiah, Ecaterina Elena Dumbrava, Daniel D. Karp, Filip Janku, Funda Meric‐Bernstam, Nizar M. Tannir, Aung Naing

Get full text

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types by Vivek Subbiah, Samuel J Klempner, Neeraj Agarwal, David P Carbone, Amit Mahipal, Shilpa Gupta, David Fabrizio, Jeffrey S Ross, Gerald Li, David R Gandara, Miles C Andrews, Jonathan W Riess, Ramez N Eskander, Ryon P Graf, Geoffrey R Oxnard, Sarah Sammons, Jeremy Snider, Lilia Bouzit, Cheryl Cho-Phan, Megan Price, Julia C F Quintanilha, Richard Sheng Poe Huang

Get full text

Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch re... by Heather Lin, Vivek Subbiah, Siqing Fu, Aung Naing, Courtney Nicholas, Shubham Pant, Chad Tang, Michael A Curran, David S Hong, Ying Yuan, Sarina A Piha-Paul, Jordi Rodon Ahnert, Timonthy A Yap, Apostolia M Tsimberidou, Daniel D Karp, Anupallavi Srinivasamani, Coline Couillault, Genevieve P Hartley, James Dai, Ecaterina E Ileana Dumbrava, Paola Guerrero, Sarah Dhebat, Theresa Proia

Get full text